Related Experiment Video
Updated: May 12, 2025

Measuring Local Anaphylaxis in Mice
Published on: October 14, 2014
Shifting perspectives: diphenhydramine usage in anaphylaxis and urticaria across US emergency departments
Jazeb Ifikhar1, Darby Sparks1, Amy D Hendrix-Dicken1
1University of Oklahoma School of Community Medicine, Department of Pediatrics, 4502 E 41st St, Tulsa, OK 74135, USA.
Background:
In recent years, the medical community's view on diphenhydramine for urticaria and anaphylaxis has shifted due to its side effects and the efficacy of second-generation antihistamines. The AAAAI's 2020 anaphylaxis guidelines discourage the use of first-generation antihistamines in the acute phase or to prevent biphasic reactions.
Objective:
Our study aimed to evaluate the usage of diphenhydramine in US emergency departments (EDs) for treating anaphylaxis and urticaria between 2019 and 2021, while also investigating the potential impact of the 2020 AAAAI guidelines on its utilization.
Methods:
A cross-sectional analysis was conducted using data from the Centers for Disease Control and Prevention's National Hospital Ambulatory Medical Care Survey (NHAMCS) spanning 2019-2021. NHAMCS collects nationwide data on patient visits to various healthcare facilities. This study focused on emergency department (ED) data, specifically examining patients with ICD-10 codes for anaphylaxis or urticaria who received at least one prescribed/given medication. Diphenhydramine administration was identified based on drug records. Design-based Pearson chi-square analysis with a significance threshold of P < .050 was employed.
Results:
Out of 450 cases with anaphylaxis and/or urticaria, 61.99 % (n = 276) involved diphenhydramine administration. Rates for anaphylaxis, urticaria, and both conditions were 57.99 % (n = 170), 69.45 % (n = 88), and 73.4 % (n = 18) respectively. No significant change in diphenhydramine use from 2019 to 2021 was found (P = .9421).
Conclusion:
Our study indicates stagnant ED practices regarding diphenhydramine despite evolving guidelines. Bridging the gap between evidence and practice is crucial for patient care for urticaria and anaphylaxis. Future research should identify barriers hindering guideline adoption in US EDs.
Related Concept Videos
Allergic Reactions
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in...
Allergic Drug Reactions

